<DOC>
	<DOCNO>NCT02447302</DOCNO>
	<brief_summary>The purpose study determine whether APD334 safe effective treatment ulcerative colitis .</brief_summary>
	<brief_title>Safety Efficacy APD334 Patients With Ulcerative Colitis</brief_title>
	<detailed_description />
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Colitis</mesh_term>
	<criteria>Moderately severely active ulcerative colitis define 3component Mayo Clinic score Evidence colonic ulcerative colitis activity endoscopy Within 30 day prior randomization , receipt follow treatment underlying disease : Nonbiologic therapy ( eg , cyclosporine , tacrolimus , tofacitinib , thalidomide ) , nonbiologic investigational therapy approve nonbiologic therapy investigational protocol Within 60 day prior randomization , receipt following : Infliximab , adalimumab , golimumab , certolizumab investigational approve biologic agent Any prior exposure natalizumab , efalizumab , rituximab</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>